AKT-IN-3 |
Katalog-Nr.GC35275 |
AKT-IN-3 (Verbindung E22) ist ein potenter, oral aktiver Akt-Inhibitor mit niedrigem hERG-Wert, mit 1,4 nM, 1,2 nM und 1,7 nM fÜr Akt1, Akt2 bzw. Akt3. AKT-IN-3 (Verbindung E22) zeigt auch eine gute inhibitorische AktivitÄt gegenÜber anderen Kinasen der AGC-Familie, wie PKA, PKC, ROCK1, RSK1, P70S6K und SGK. AKT-IN-3 (Verbindung E22) induziert Apoptose und hemmt die Metastasierung von Krebszellen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2374740-21-1
Sample solution is provided at 25 µL, 10mM.
AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking Akt inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells[1]. Akt1|1.4 nM (IC50)|Akt2|1.2 nM (IC50)|Akt3|1.7 nM (IC50)|PKA|0.3 nM (IC50)|P70S6K|8.9 (IC50)
[1]. Dong X, et al. Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design. J Med Chem. 2019 Aug 8;62(15):7264-7288.
Average Rating: 5
(Based on Reviews and 14 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *